文献速递生殖医学

体外受精/卵胞浆内单精子注射启动时个体化与标准促卵泡激素剂量的随机对照试验:第二部分 预测高反应者

Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
PubMed 文献 · Hum Reprod · 2017-01-01

这项开放标签多中心随机对照试验纳入抗苗勒管激素窦卵泡计数>15、拟行体外受精/卵胞浆内单精子注射的女性,比较每日促卵泡激素100 IU与150 IU。两组累积活产率无显著差异,低剂量组任何级别卵巢过度刺激综合征发生率更低,但重度卵巢过度刺激综合征发生率无差异,且低剂量组首个周期取消率更高。

要点

  • 预测高反应(窦卵泡计数>15)女性中,促卵泡激素100 IU/日与150 IU/日的累积活产率无显著差异。
  • 低剂量组任何级别卵巢过度刺激综合征发生率更低(5.2% vs 11.8%),但重度卵巢过度刺激综合征发生率无差异。
  • 低剂量组首个周期取消率更高,且经济分析未显示低剂量策略更便宜。

核心结论

  • 在预测高反应(窦卵泡计数>15)拟行体外受精/卵胞浆内单精子注射的女性中,减少促卵泡激素剂量不影响活产率,可降低轻度和中度卵巢过度刺激综合征发生率,但对重度卵巢过度刺激综合征无影响。

研究设计与样本

  • 2011年5月至2014年5月开展的一项开放标签、多中心随机对照试验,纳入月经周期规律且窦卵泡计数>15的女性,排除多囊卵巢综合征(鹿特丹标准)患者。
  • 共随机分配255例至促卵泡激素100 IU/日组、266例至150 IU/日组;主要结局为随机分组后18个月内获得持续妊娠并活产。
  • 该随机对照试验嵌套于一项评估超过1500例女性的队列研究,原预计随机化300例预测高反应者。

主要发现

  • 累积活产率在100 IU组为66.3%(169/255),在150 IU组为69.5%(185/266),相对风险(RR)0.95(95%CI 0.85-1.07),P=0.423。
  • 任何级别卵巢过度刺激综合征发生率在100 IU组为5.2%,在150 IU组为11.8%,RR 0.44(95%CI 0.28-0.71),P=0.001。
  • 重度卵巢过度刺激综合征发生率在100 IU组为1.3%,在150 IU组为1.1%,RR 1.25(95%CI 0.38-4.07),P=0.728。

关键数值与推荐

  • 预测高反应定义为窦卵泡计数>15。
  • 促卵泡激素起始剂量为100 IU/日或150 IU/日;后续周期允许根据预设标准调整剂量,减量组最大调整25 IU,标准组最大调整50 IU。
  • 主要结局为随机分组后18个月内获得持续妊娠并活产。

临床怎么用

  • 作者认为,对预测高反应拟行体外受精/卵胞浆内单精子注射的女性,减少促卵泡激素剂量不影响活产率。
  • 作者指出,较低促卵泡激素剂量可降低轻度和中度卵巢过度刺激综合征发生率,但对重度卵巢过度刺激综合征无影响。
  • 作者建议,未来针对预测高反应女性的卵巢储备检测指导 dosing 研究应比较各种安全管理策略,并以临床相关的安全性结局为效能计算依据,同时评估活产率的非劣效性。

局限性

  • 尽管有培训方案,窦卵泡计数仍可能存在观察者间变异。
  • 虽然提供了严格的取消标准,但不能排除减量组选择性取消(尤其因低反应),因为观察者未对促卵泡激素剂量设盲,且后续周期允许小幅剂量调整。
  • 由于该随机对照试验嵌套于较大队列研究,本研究的效能不可避免地低于应有水平。
  • 参与者体质指数从国际视角看相对较低,可能限制研究结果的普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does a reduced FSH dose in women with a predicted hyper response, apparent from a high antral follicle count (AFC), who are scheduled for IVF/ICSI lead to a different outcome with respect to cumulative live birth rate and safety? SUMMARY ANSWER: Although in women with a predicted hyper response (AFC > 15) undergoing IVF/ICSI a reduced FSH dose (100 IU per day) results in similar cumulative live birth rates and a lower occurrence of any grade of ovarian hyperstimulation syndrome (OHSS) as compared to a standard dose (150 IU/day), a higher first cycle cancellation rate and similar severe OHSS rate were observed. WHAT IS KNOWN ALREADY: Excessive ovarian response to controlled ovarian stimulation (COS) for IVF/ICSI may result in increased rates of cycle cancellation, the occurrence of OHSS and suboptimal live birth rates. In women scheduled for IVF/ICSI, an ovarian reserve test (ORT) can be used to predict response to COS. No consensus has been reached on whether ORT-based FSH dosing improves effectiveness and safety in women with a predicted hyper response. STUDY DESIGN SIZE, DURATION: Between May 2011 and May 2014, we performed an open-label, multicentre RCT in women with regular menstrual cycles and an AFC > 15. Women with polycystic ovary syndrome (Rotterdam criteria) were excluded. The primary outcome was ongoing pregnancy achieved within 18 months after randomization and resulting in a live birth. Secondary outcomes included the occurrence of OHSS and cost-effectiveness. Since this RCT was embedded in a cohort study assessing over 1500 women, we expected to randomize 300 predicted hyper responders. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with an AFC > 15 were randomized to an FSH dose of 100 IU or 150 IU/day. In both groups, dose adjustment was allowed in subsequent cycles (maximum 25 IU in the reduced and 50 IU in the standard group) based on pre-specified criteria. Both effectiveness and cost-effectiveness were evaluated from an intention-to-treat perspective. MAIN RESULTS AND THE ROLE OF CHANCE: We randomized 255 women to a daily FSH dose of 100 IU and 266 women to a daily FSH dose of 150 IU. The cumulative live birth rate was 66.3% (169/255) in the reduced versus 69.5% (185/266) in the standard group (relative risk (RR) 0.95 [95%CI, 0.85-1.07], P = 0.423). The occurrence of any grade of OHSS was lower after a lower FSH dose (5.2% versus 11.8%, RR 0.44 [95%CI, 0.28-0.71], P = 0.001), but the occurrence of severe OHSS did not differ (1.3% versus 1.1%, RR 1.25 [95%CI, 0.38-4.07], P = 0.728). As dose reduction was not less expensive (€4.622 versus €4.714, delta costs/woman €92 [95%CI, -479-325]), there was no dominant strategy in the economic analysis. LIMITATIONS, REASONS FOR CAUTION: Despite our training programme, the AFC might have suffered from inter-observer variation. Although strict cancellation criteria were provided, selective cancelling in the reduced dose group (for poor response in particular) cannot be excluded as observers were not blinded for the FSH dose and small dose adjustments were allowed in subsequent cycles. However, as first cycle live birth rates did not differ from the cumulative results, the open design probably did not mask a potential benefit for the reduced dosing group. As this RCT was embedded in a larger cohort study, the power in this study was unavoidably lower than it should be. Participants had a relatively low BMI from an international perspective, which may limit generalization of the findings. WIDER IMPLICATIONS OF THE FINDINGS: In women with a predicted hyper response scheduled for IVF/ICSI, a reduced FSH dose does not affect live birth rates. A lower FSH dose did reduce the incidence of mild and moderate OHSS, but had no impact on severe OHSS. Future research into ORT-based dosing in women with a predicted hyper response should compare various safety management strategies and should be powered on a clinically relevant safety outcome while assessing non-inferiority towards live birth rates. STUDY FUNDING/COMPETING INTEREST(S): This trial was funded by The Netherlands Organization for Health Research and Development (ZonMW, Project Number 171102020). SCO, TCvT and HLT received an unrestricted research grant from Merck Serono (the Netherlands). CBL receives grants from Merck, Ferring and Guerbet. BWJM is supported by a NHMRC Practitioner Fellowship (GNT1082548) and reports consultancy for OvsEva, Merck and Guerbet. FJMB receives monetary compensation as a member of the external advisory board for Ferring pharmaceutics BV and Merck Serono for consultancy work for Gedeon Richter (Belgium) and Roche Diagnostics (Switzerland) and for a research cooperation with Ansh Labs (USA). All other authors have nothing to declare. TRIAL REGISTRATION NUMBER: Registered at the ICMJE-recognized Dutch Trial Registry (www.trialregister.nl). Registration number: NTR2657. TRIAL REGISTRATION DATE: 20 December 2010. DATE OF FIRST PATIENT’S ENROLMENT: 12 May 2011.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Oudshoorn SC, van Tilborg TC, Eijkemans MJC, et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder. Hum Reprod. 2017. PMID: 29121269. doi:10.1093/humrep/dex319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。